Anti-Saccharomyces cerevisiae antibodies in patients with COVID-19

Anti-Saccharomyces cerevisiae antibodies (ASCA) have been described in many autoimmune diseases (AIDs). Coronavirus disease 2019 (COVID-19) could trigger AIDs. This study aimed to determine the frequency of ASCA in patients with COVID-19. This study included 88 adult patients with severe COVID-19, 5...

Full description

Saved in:

Bibliographic Details
Published in:	Arab journal of gastroenterology Vol. 23; no. 4; pp. 241 - 245
Main Authors:	Melayah, Sarra, Mankaï, Amani, Jemni, Malek, Chaben, Arij Ben, Ghozzi, Mariam, Ben Abdelkrim, Asma, Ach, Kousay, Ghariani, Nadia, Denguezli, Mohamed, Benzarti, Wafa, Benzarti, Mohamed, Melayah, Salma, Naija, Walid, Ghedira, Ibtissem
Format:	Journal Article
Language:	English
Published:	Egypt Elsevier B.V 01-11-2022 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V
Subjects:	Adults Anti-Saccharomyces cerevisiae antibodies mild COVID-19 severe COVID-19 COVID-19 SARS-CoV-2 MBL severe COVID-19 Adults mild COVID-19 AID Anti-Saccharomyces cerevisiae antibodies ASCA
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Anti-Saccharomyces cerevisiae antibodies (ASCA) have been described in many autoimmune diseases (AIDs). Coronavirus disease 2019 (COVID-19) could trigger AIDs. This study aimed to determine the frequency of ASCA in patients with COVID-19. This study included 88 adult patients with severe COVID-19, 51 mild COVID-19, and 160 healthy blood donors. ASCA of isotype immunoglobulin (Ig)G and IgA were detected by enzyme-linked immunosorbent assay. The frequency of ASCA (IgG or IgA) was significantly higher in patients with severe COVID-19 (21.6 % vs 3.7 %, p < 10−3) and in patients with mild COVID-19 than in the healthy controls (13.7 % vs 3.7 %, p = 0.03). ASCA-IgA was significantly more frequent in patients with severe COVID-19 than in healthy controls (15.9 % vs 0.6 %, p < 10−3). ASCA-IgG was significantly more frequent in patients with mild COVID-19 than in healthy controls (13.7 % vs 3.1 %, p = 0.02). ASCA (IgG or IgA) were more frequent in severe than in mild COVID-19, but the difference was not statistically significant (21.6 % vs 13.7 %). ASCA-IgA was significantly more frequent in patients with severe than those with mild COVID-19 (15.9 % vs 0 %, p = 0.003). The mean ASCA-IgG and ASCA-IgA levels were significantly higher in patients with severe COVID-19 than in healthy controls (5.8 U/mL ± 11.8 vs 2.3 U/mL ± 2.8, p < 10−3 and 9.2 U/mL ± 21.5 vs 3.4 U/mL ± 1.7, respectively, p < 10−3). The mean ASCA-IgG levels were significantly higher in patients with mild COVID-19 than in healthy controls (6.2 U/mL ± 12.9 vs 2.3 U/mL ± 2.8, p < 10−3). The mean ASCA-IgA levels were significantly higher in patients with severe than in those with mild COVID-19 (9.2 U/mL ± 21.5 vs 2.6 U/mL ± 1.2, p = 0.03). ASCA was more frequent in patients with COVID-19 than in healthy controls.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1687-1979 2090-2387
DOI:	10.1016/j.ajg.2022.07.001